Oncolytics Biotech's long-term debt is $340K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), ONCY shows a long-term debt of $340K. That compares with $710K in the prior-year period — down 51.8% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ONCY's long-term debt is now $340K (was $710K) — a 51.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Oncolytics Biotech is outperforming or lagging.
Tracking ONCY's long-term debt over time shows whether Oncolytics Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $340K That compares with $710K in the prior-year period — down 51.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Oncolytics Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $340K) with ownership activity and broader fundamentals.
Oncolytics Biotech's long-term debt is $340K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.